Raf kinase inhibitor protein inhibits cholangiocarcinoma cell metastasis by downregulating matrix metalloproteinase 9 and upregulating tissue inhibitor of metalloproteinase 4 expression

Oncology Letters

Volumn 9, Issue 1, 2015, Pages 15-24

  Ma, Junji ^a   Shi, Junli ^a   Zhao, Dongqiang ^a   Cheng, Lijuan ^a   Wang, Wenbin ^a   Li, Fangfang ^a   Jiang, Xiaoyu ^b   Jiang, Huiqing ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cholangiocarcinoma; Invasion; Migration; Raf kinase inhibitor protein

Indexed keywords

ADENOVIRUS VECTOR; CYTOKERATIN 19; GELATINASE B; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 4;

ADULT; APOPTOSIS ASSAY; ARTICLE; BILE DUCT CARCINOMA; CELL DIFFERENTIATION; CELL INVASION ASSAY; CELL MIGRATION ASSAY; CELL PROLIFERATION ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84911411835     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2637     Document Type: Article

References (32)

1. Francis H, Alpini G and DeMorrow S: Recent advances in the regulation of cholangiocarcinoma growth. Am J Physiol Gastrointest Liver Physiol 299: G1-G9, 2010.
2. Marsh Rde W, Alonzo M, Bajaj S, et al: Comprehensive review of the diagnosis and treatment of biliary tract cancer 2012. Part I: diagnosis-clinical staging and pathology. J Surg Oncol 106: 332-338, 2012.
3. von Hahn T, Ciesek S, Wegener G, et al: Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. Scand J Gastroenterol 46: 1092-1098, 2011.
4. Marzioni M, Saccomanno S, Candelaresi C, et al: Clinical implications of novel aspects of biliary pathophysiology. Dig Liver Dis 42: 238-244, 2010.
5. Ciombor KK and Goff LW: Current therapy and future directions in biliary tract malignancies. Curr Treat Options Oncol 14: 337-349, 2013.
6. Yeung K, Seitz T, Li S, et al: Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 401: 173-177, 1999.
7. Yeung KC, Rose DW, Dhillon AS, et al: Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol 21: 7207-7217, 2001.
8. Deiss K, Kisker C, Lohse MJ and Lorenz K: Raf kinase inhibitor protein (RKIP) dimer formation controls its target switch from Raf1 to G protein-coupled receptor kinase (GRK) 2. J Biol Chem 287: 23407-23417, 2012.
9. Chatterjee D, Bai Y, Wang Z, et al: RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem 279: 17515-17523, 2004.
10. Moon A, Park JY, Sung JY, Park YK and Kim YW: Reduced expression of Raf-1 kinase inhibitory protein in renal cell carcinoma: a significant prognostic marker. Pathology 44: 534-539, 2012.
11. Yun J, Frankenberger CA, Kuo WL, et al: Signalling pathway for RKIP and Let-7 regulates and predicts metastatic breast cancer. EMBO J 30: 4500-4514, 2011.
12. Beshir AB, Ren G, Magpusao AN, et al: Raf kinase inhibitor protein suppresses nuclear factor-κB-dependent cancer cell invasion through negative regulation of matrix metalloproteinase expression. Cancer Lett 299: 137-149, 2010.
13. Ma J, Li F, Liu L, et al: Raf kinase inhibitor protein inhibits cell proliferation but promotes cell migration in rat hepatic stellate cells. Liver Int 29: 567-574, 2009.
14. Zhao D, Ma J, Shi J, et al: Raf kinase inhibitor protein inhibits esophageal cancer cell invasion through downregulation of matrix metalloproteinase expression. Oncol Rep 30: 304-312, 2013.
15. Birner P, Jesch B, Schultheis A and Schoppmann SF: RAF-kinase inhibitor protein (RKIP) downregulation in esophageal cancer and its metastases. Clin Exp Metastasis 29: 551-559, 2012.
16. Braconi C and Patel T: Cholangiocarcinoma: new insights into disease pathogenesis and biology. Infect Dis Clin North Am 24: 871-884, 2010.
17. Nathan H, Aloia TA, Vauthey JN, et al: A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol 16: 14-22, 2009.
18. Ribero D, Nuzzo G, Amisano M, et al: Comparison of the prognostic accuracy of the sixth and seventh editions of the TNM classification for intrahepatic cholangiocarcinoma. HPB (Oxford) 13: 198-205, 2011.
19. Lorenz K, Lohse MJ and Quitterer U: Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature 426: 574-579, 2003.
20. Deiss K, Kisker C, Lohse MJ and Lorenz K: Raf kinase inhibitor protein (RKIP) dimer formation controls its target switch from Raf1 to G protein-coupled receptor kinase (GRK) 2. J Biol Chem 287: 23407-23417, 2012.
21. Escara-Wilke J, Yeung K and Keller ET: Raf kinase inhibitor protein (RKIP) in cancer. Cancer Metastasis Rev 31: 615-620, 2012.
22. Maeda T, Kajiyama K, Adachi E, Takenaka K, Sugimachi K and Tsuneyoshi M: The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver. Mod Pathol 9: 901-909, 1996.
23. Kim HS, Lee SH, Won KY, et al: Expression of Raf-1 kinase inhibitory protein in carcinoma of the ampulla of Vater. Virchows Arch 460: 61-68, 2012.
24. Al-Mulla F, Bitar MS, Taqi Z and Yeung KC: RKIP: much more than Raf kinase inhibitory protein. J Cell Physiol 228: 1688-1702, 2013.
25. Lódi C, Szabó E, Holczbauer A, et al: Claudin-4 differentiates biliary tract cancers from hepatocellular carcinomas. Mod Pathol 19: 460-469, 2006.
26. Thummarati P, Wijitburaphat S, Prasopthum A, et al: High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis. World J Gastroenterol 18: 244-250, 2012.
27. Park SY, Kim JH, Won HJ, Shin YM and Kim PN: Radiofrequency ablation of hepatic metastases after curative resection of extrahepatic cholangiocarcinoma. AJR Am J Roentgenol 197: W1129-W1134, 2011.
28. Wang Q, Tang H, Yin S and Dong C: Downregulation of microRNA-138 enhances the proliferation, migration and invasion of cholangiocarcinoma cells through the upregulation of RhoC/p-ERK/MMP-2/MMP-9. Oncol Rep 29: 2046-2052, 2013.
29. Leelawat K, Sakchinabut S, Narong S and Wannaprasert J: Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy. BMC Gastroenterol 9: 30, 2009.
30. French JJ, Midwinter MJ, Bennett MK, Manas DM and Charnley RM: A matrix metalloproteinase inhibitor to treat unresectable cholangiocarcinoma. HPB (Oxford) 7: 289-291, 2005.
31. Jo Chae K, Rha SY, Oh BK, et al: Expression of matrix metalloproteinase-2 and -9 and tissue inhibitor of metalloproteinase-1 and -2 in intraductal and nonintraductal growth type of cholangiocarcinoma. Am J Gastroenterol 99: 68-75, 2004.
32. Selaru FM, Olaru AV, Kan T, et al: MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 49: 1595-1601, 2009.